What caused the significant drop in total revenue?

The significant drop in total revenue was primarily due to the absence of collaboration revenue in the current period. In the prior year's comparable period, the company recognized substantial revenue from a collaboration agreement with BMS, including a $150 million termination fee. This revenue stream was not present in the second quarter of 2020.

What is driving the increase in research and development (R&D) expenses?

R&D expenses increased by 25.0% to $286.0 million for the quarter. This increase is attributed to the advancement of clinical drug candidates, including zanubrutinib and tislelizumab, the commencement of co-development expense recognition related to the Amgen collaboration, and increased internal R&D spending driven by hiring more R&D personnel and higher materials costs for manufacturing drug candidates.

What is the company's current liquidity and cash position?

BeiGene maintains a strong liquidity position, with cash, cash equivalents, and restricted cash totaling $1.35 billion as of June 30, 2020. This was further bolstered by a successful registered direct offering in July 2020, which raised approximately $2.1 billion. This robust cash balance is expected to fund the company's operations and strategic initiatives for the foreseeable future.

Are there any significant supply chain or product-specific issues?

Yes, the company is experiencing a disruption in the supply of ABRAXANE® in China. This is due to a suspension of importation, sales, and use by China's NMPA, stemming from inspection findings at BMS's contract manufacturing facility. BMS has initiated a voluntary recall of existing stock, leading to an inability for BeiGene to generate revenue from ABRAXANE® until the suspension is lifted and supply is restored.

ONC/BEIGF 10-Q Quarterly Report Q2 FY2020

Q: How did the company's product revenues perform?

Net product revenues showed a positive trend, increasing by 12.9% to $65.6 million for the three months ended June 30, 2020. This growth was driven by strong sales of internally developed products like tislelizumab and BRUKINSA®, which saw increased adoption in China and the US. However, this growth was partially offset by a significant decrease in ABRAXANE® sales due to a regulatory suspension in China.

Summary

BeiGene, Ltd. (ONC) reported its financial results for the second quarter and the first six months of 2020. The company experienced a significant year-over-year decline in total revenues, primarily due to the absence of collaboration revenue compared to the previous year's period, which included a substantial termination fee from a BMS collaboration. However, net product revenues showed growth, driven by increased sales of internally developed products like tislelizumab and BRUKINSA®, partially offset by a decline in ABRAXANE® sales due to regulatory suspension in China. Research and development expenses saw a notable increase, reflecting continued investment in clinical drug candidates and co-development obligations with Amgen. Selling, general, and administrative expenses also rose significantly, driven by increased headcount and expansion of commercial operations. Despite reporting a substantial net loss, the company's cash position remained strong, bolstered by a significant equity financing round in July 2020, providing ample liquidity for future operations and strategic initiatives. Operationally, the company advanced its key drug candidates, with regulatory updates and clinical trial progress being key themes. The increase in R&D spending is indicative of BeiGene's commitment to its robust pipeline. Investors should note the significant increase in operating expenses, which, while supporting growth, contributed to the widened net loss. The substantial cash reserves provide a buffer against these operating losses and allow for continued investment in development and commercialization efforts.

Financial Highlights

53 data points

Beta

Revenue

$65.64M

0.8% Gross Margin

Net Income

-$336.32M

-5.1% Net Margin

EPS (Diluted)

$-0.33

Total Assets

$3.90B

Cash & Equivalents

$1.35B

Free Cash Flow

-$295.55M

Financial Statements

Beta

Revenue	$65.64M
Cost of Revenue	$14.31M
Gross Profit	$51.33M
R&D Expenses	$285.97M
SG&A Expenses	$124.05M
Operating Expenses	$424.51M
Operating Income	-$358.88M
Interest Expense	$1.89M
Net Income	-$336.32M
EPS (Basic)	$-0.33
Shares Outstanding (Basic)	1.01B
Shares Outstanding (Diluted)	1.01B

Key Highlights

1Total revenues decreased by 73.0% to $65.6 million for the three months ended June 30, 2020, compared to $243.3 million in the prior year period, mainly due to the cessation of collaboration revenue.
2Net product revenues increased by 12.9% to $65.6 million for the three months ended June 30, 2020, driven by strong sales of tislelizumab and BRUKINSA®, partly offset by reduced ABRAXANE® sales.
3Research and development expenses increased by 25.0% to $286.0 million for Q2 2020, reflecting ongoing investment in clinical programs and the Amgen co-development obligation.
4Selling, general, and administrative expenses increased by 50.8% to $124.0 million for Q2 2020, driven by increased headcount and expanded commercial operations.
5The company reported a net loss attributable to BeiGene, Ltd. of $335.2 million for the three months ended June 30, 2020, compared to $85.6 million in the prior year period.
6Cash, cash equivalents, and restricted cash at the end of the period was $1.35 billion, with a strong liquidity position further enhanced by a $2.1 billion equity offering in July 2020.
7The company is facing disruptions in ABRAXANE® supply in China due to a regulatory suspension and recall by BMS.

BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2020

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions